Statistics show that most of the diseases that cause significant mortality in Africa are treatable or manageable with existing drugs.  What stands in the way of treatment, and hence survival, is access to affordable drugs.  Most countries in Africa do not offer a defined healthcare plan.  A certain portion of the population can afford to buy medication and others cannot.  The key to attaining an effective impact on health in the region is to establish a profitable business producing modern and affordable drugs.

LaGray will be the first to manufacture APIs in West Africa and the first fully self-sufficient pharmaceuticals manufacturer in the region. We are currently building capacity in Ghana to develop and manufacture active pharmaceutical ingredients and seamlessly integrate these into high value finished dosage forms for the treatment of endemic diseases in sub-Saharan Africa. 

Our focus on local health-care needs will one day lead to new treatments for a number of diseases that have largely escaped attention, but have been devastating to the health and economies of the region.